Introduction {#s0005}
============

Unplanned readmission is a costly and largely preventable healthcare burden. In their landmark article, Jencks et al. revealed that readmissions account for an estimated USD17.4 billion in annual spending by Medicare (US) ([@bb0105]). Reducing readmission rates has become an imperative among healthcare policymakers. In the United States, the Affordable Care Act authorizes Medicare to impose reimbursement penalties on hospitals for excessive readmissions ([@bb0125]). Causes of readmissions are multi-factorial and many interventions targeted at high-risk patients have been attempted hitherto, albeit with varying degree success ([@bb0090]).

Increased age, multiple comorbidities and polypharmacy, widely defined as the use of five or more drugs, have been identified as contributory factors with the highest risk of readmission [@bb0115], [@bb0170]. While age and the presence of comorbidities are unmodifiable, polypharmacy may be addressed via a variety of ways such as medication reconciliation and adoption of judicious prescribing strategies [@bb0085]. A recent study on medication discontinuation among elderly patients successfully discontinued 311 medications in 64 patients without recurrence or worsening of clinical symptoms. However, as acknowledged by the authors, most of the discontinued medications were clearly inappropriate thus reasonably discontinued ([@bb0075]). Such practice may not always be feasible.

Relatedly, the reduction of dosing frequencies, hence number of doses per day, was suggested as an alternative strategy where drug discontinuation may engender adverse outcomes ([@bb0075], [@bb0070]). Prescriptions with less frequent dosing regimens have been shown to decrease the occurrence of diseases or symptomatology associated with the drug therapy (i.e. drug-related problems (DRPs)) ([@bb0150], [@bb0095], [@bb0160]). However, the association between number of doses per day and readmission frequency remains unclear. The present study investigates the association between number of doses per day and the number of readmissions.

Methods {#s0010}
=======

Study design {#s0030}
------------

We performed a retrospective, cross-sectional study involving 432 patients who had at least one readmission between January 1, 2013 and March 31, 2013. Institutional review board approval and waiver of consent were obtained from the National Healthcare Group, Singapore.

Patient population {#s0035}
------------------

Subjects included patients from a general and acute care hospital in Singapore. Patients who were 18 years and above and readmitted to any public hospital in Singapore within the defined study period were included in the study. Subjects with inaccessible medical records were excluded from the study.

Data collection {#s0040}
---------------

All data were collected through the national electronic medical records database, a shared database across all public healthcare institutions in Singapore. Readmission was defined as each unscheduled admission occurring within 15 days of discharge. For patients with multiple readmissions, each episode was counted as a separate readmission.

Details recorded for each readmission included age, sex, race, presence of specific co-morbidities from the Charlson Comorbidity Index ([@bb0035]), number of readmissions, number of medications and number of doses per day dispensed during the previous discharge. Total number of medications included all dispensed medications of different dosage forms or active ingredients. Different dosage forms containing the same active ingredient were counted as separate medications. For instance, a patient using betamethasone cream and betamethasone ointment was considered to have been prescribed two different medications. Different amounts per dosage unit of the same active ingredient in the same dosage form were not counted separately if they were administered with the same dosing frequency. For example, a patient taking one 5 mg enalapril tablet twice daily and one 10 mg enalapril tablet twice daily was considered to be taking only one medication with 2 doses per day.

Number of doses per day referred to the cumulative number of doses for all dispensed medications per day. Doses of medications prescribed on an 'as needed' basis were tabulated based on the maximum number of prescribed doses per day. For example, "two 500 mg paracetamol tablets to be taken orally every 6 hourly as needed" was counted as four doses of paracetamol 1 g per day. Doses prescribed on a non-daily dosing schedule, such as once-weekly dose of alendronate, were recorded as a single daily dose.

All readmission records were reviewed for DRPs diagnosed on admission. Readmission was treated as DRP-related only when it was explicitly stated in the electronic case notes to be caused by a DRP. Documentation of a DRP was based on implicit physician judgment. DRP categories were adapted from those defined by Strand et al. and include patient non-compliance, over-dosage and sub-optimal dosage of the indicated medication and adverse drug reactions ([@bb0160]). Non-compliance referred to the failure to adhere to the prescribed drug regimen in terms of doses and dosing schedules ([@bb0165]).

Statistical analysis {#s0045}
--------------------

Descriptive statistics was calculated and data was presented as mean ± standard deviation or number and percentage. Univariate regression analyses were performed to identify the prognostic value of each variable in influencing the outcome of number of readmissions in our study population. Variables which were found to be significantly (*p* \< 0.05) associated with the outcome variable of number of readmissions in the univariate analysis were subsequently included in a multivariate regression model. Backward elimination was used to simplify the multivariate model, removing variables that had a *p* value of ≥ 0.05 sequentially, until all remaining variables were significantly associated with the number of readmissions. To account for non-independence and count nature of the dependent variable, generalized linear mixed models (GLMMs) with both Poisson and negative binomial errors were used and compared. Multicollinearity was avoided by ensuring variance inflation factor (VIF) was less than 3 throughout the multivariable regression analyses. All statistical analyses were carried out using the R statistical programing language (version 3.0.1) and GLMMs were fitted using the GLMMadmb package ([@bb0065]).

Results {#s0015}
=======

There were a total of 649 unplanned readmissions during the study period and most (66.6%) were first-time readmissions. The mean age of our sample was 67.7 ± 16.2 years. The mean number of doses per day and number of medications were 18.0 ± 8.0 and 10.0 ± 4.4 respectively. There is a total of 103 DRP-related readmissions, of which non-compliance (5.6%) was the most common iatrogenic cause of readmission. Demographics and clinical characteristics of the readmission events are summarized in [Table 1](#t0005){ref-type="table"}.

Significant univariable correlates (*p* \< 0.05) include number of doses per day, number of medications, race not of Chinese, Malay or Indian race (classified as 'other' race), liver disease, anemia and schizophrenia, as shown in [Table 2](#t0010){ref-type="table"}.

There was no difference in results when GLMMs were modeled using Poisson and negative binomial errors. From the GLMM analysis using number of doses per day, factors that significantly increased the number of readmissions in the readmitted population were liver disease (β = 0.33; *p* = 0.002), diagnosis of schizophrenia (β = 0.44; *p* \< 0.001), documented non-compliance (β = 0.32; *p* = 0.009), number of doses per day (β = 0.01; *p* = 0.003) and 'other' race (β = 0.25; *p* = 0.02), as depicted in [Table 3a](#t0015){ref-type="table"}. When the 'number of doses per day' variable was transformed and expressed in terms of number of medications prescribed, significant variables were likewise, liver disease (β = 0.32; *p* = 0.003), diagnosis of schizophrenia (β = 0.44; *p* \< 0.001), documented non-compliance (β = 0.32; *p* = 0.009) and 'other' race (β = 0.25; *p* = 0.02) and number of medications (β = 0.02; *p* = 0.002), as seen in [Table 3b](#t0020){ref-type="table"}.

Discussion {#s0020}
==========

We found a significant positive association between number of readmissions and polypharmacy, expressed in terms of number of doses per day and number of medications prescribed. In addition, there was a significant association between non-compliance and the number of readmissions.

Non-compliance is among the most commonly reported iatrogenic causes of readmission (33--69%) ([@bb0025], [@bb0155], [@bb0045]). Our study supports this finding, with non-compliance constituting 39 of the 103 DRP-related readmissions. Failure to comply with dosage regimens can lead to suboptimal disease control or rebound symptoms from abrupt cessation, requiring readmissions ([@bb0075]). Barriers to medication adherence are largely under the patient\'s control, with forgetfulness being the most commonly cited (30%) ([@bb0140]). Practitioner-led interventions such as regimen simplification are useful in improving compliance ([@bb0060]). Evidence to date suggests that patients adhere more to dosage regimens with fewer medications and in turn are less likely to be hospitalized ([@bb0060], [@bb0050]).

Unfortunately, combination therapies are indicated in patients with multiple comorbidities especially if the diseases are poorly controlled ([@bb0155], [@bb0135]). For instance, the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC) recommends that 2 or more antihypertensive drugs are required to achieve desired blood pressure levels ([@bb0100]). The concurrent administration of multiple antihypertensives may increase patient\'s risk of severe hypotension necessitating emergency visit and admission ([@bb0015]). Such a dilemma is not uncommon in other chronic conditions where polypharmacy is necessary for disease control but is associated with undesired outcomes such as readmissions, as seen in our study ([@bb0015]).

The indispensability of multi-drug therapies underscores the need for alternative approaches to mitigate the heightened risks of non-compliance and readmissions among patients with multiple comorbidities. Reducing the total number of daily doses can effectively encourage patient adherence to their prescribed dosage regimen and improve disease control ([@bb0095], [@bb0025], [@bb0045]). In trials comparing once-daily and once-weekly fluoxetine, patients on once-weekly doses displayed greater adherence rates ([@bb0040], [@bb0055]). In a randomized-controlled trial comparing once-daily gliclazide with twice-daily glibenclamide, fasting glucose and HbA1c were better controlled in patients on a once-daily gliclazide regimen ([@bb0120]).

Despite vast findings on the advantages of reducing number of doses per day, there is no prior evidence on how this intervention will improve hospital readmission rates. From our study findings, readmission frequency is positively correlated with number of doses per day. This suggests that reducing dosing frequency through combination therapies may minimize chances of unplanned readmissions. Undeniably, this strategy is not always applicable, for example, when longer-acting alternatives are unavailable or unsuitable. In these instances, other compliance measures such as constant reminders on the correct use of medications and patient involvement in the pharmaceutical care plan could be utilized ([@bb0165]).

Readmission disparities among different races have been well-documented among multiethnic populations ([@bb0110]). Among elderly Medicare (US) recipients, African Americans have higher readmission rates compared to Caucasians ([@bb0110]). In comparison, our study found that only the minority race was a significant predictor of readmissions. These racial disparities may be due to an underlying differential socio-economic status among the various races ([@bb0145], [@bb0130]).

Among the comorbidities, liver disease and schizophrenia were significantly associated with readmission at the multivariable level. Liver diseases are complex with many complications such as hepatic encephalopathy, ascites and portal hypertension requiring admission ([@bb0020], [@bb0005]). For schizophrenia, the patient\'s lack of insight is a major barrier to adherence and contributor to unplanned readmissions ([@bb0005]).

Limitations {#s0050}
-----------

Unlike most studies listed in the systematic review by Kansagara et al., we used 15-day readmission instead of 30-day readmission as the study outcome ([@bb0115]). More readmission events would have been recorded had we used the 30-day readmission definition ([@bb0080]). This could have led to a potential underestimation of the actual number of DRP-related readmissions. Here, the 15-day cut-off was selected because readmissions within 15 days post-discharge was already posing a significant challenge to our healthcare institution, with approximately 6 patients readmitted each day within the defined study period.

As the association between number of doses per day and hospital readmission has never been reported, we conducted a retrospective study to assess the feasibility of a subsequent prospective study. Due to the retrospective study design, the electronic databases used in this study did not contain data on illness severity and social determinants. This is a common issue faced by other studies that relied on retrospective administrative data. In a recent systematic review, only 2 out of a total 32 studies on prediction models of hospital readmission examined the importance of disease severity ([@bb0115]). Of note, one of the two studies which studied the disease severity found that it was a significant predictor ([@bb0030], [@bb0010]). Similarly, the predictive roles of socioeconomic status, education and caregiver availability are poorly studied and remain largely inconclusive ([@bb0115]). These variables will be considered in a subsequent prospective study.

Conclusion {#s0025}
==========

Readmissions can exert a heavy financial burden on healthcare systems. Though the true proportion of preventable hospital readmissions is not known, unplanned readmissions due to non-compliance can be potentially preventable. In summary, we have demonstrated a positive association between readmission frequency and polypharmacy, as well as non-compliance. Prudent prescribing and the use of longer-acting formulations or fixed-dose combinations might minimize readmissions attributable to non-compliance or polypharmacy, and achieve substantial cost-savings.
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###### 

Demographics and clinical characteristics of events.

  ---------------------------------------------------
  Variable                  Total number of events\
                            (N = 649)
  ------------------------- -------------------------
  Age (years)               67.7 years ± 16.2

  Race                      

   Chinese                  388 (59.8)

   Malay                    122 (18.8)

   Indian                   85 (13.1)

   Others                   54 (8.3)

  Gender                    

   Male                     339 (52.2)

   Female                   310 (47.8)

  Number of doses per day   18.0 ± 8.0

  Number of medications     10.0 ± 4.4

  Co-morbidities            

   Diabetes                 299 (46.1)

   Hypertension             411 (63.3)

   Dyslipidemia             331 (51.0)

   CHD                      213 (32.8)

   CVD                      87 (13.4)

   Hemiplegia               7 (1.1)

   CHF                      33 (5.1)

   COPD                     41 (6.3)

   Asthma                   63 (9.7)

   Liver disease            50 (7.7)

   CKD                      79 (12.2)

   Ulcer disease            40 (6.2)

   Osteoarthritis           40 (6.2)

   Osteoporosis             19 (2.9)

   Gout                     45 (6.9)

   Cataract                 39 (6.0)

   Anemia                   148 (22.8)

   Cancer                   62 (9.6)

   BPH                      41 (6.3)

   Thyroid                  33 (5.1)

   Hemorrhoid               2 (0.3)

   Epilepsy                 29 (4.5)

   Dementia                 50 (7.7)

   Depression               53 (8.2)

   Alzheimer\'s disease     9 (1.4)

   Schizophrenia            30 (4.6)

   PKD                      19 (2.9)

  Types of DRPs             

   Non-compliance           39 (5.6)

   Hypoglycemia             7 (0.9)

   Hyponatremia             4 (0.6)

   Hypokalemia              4 (0.6)

   Metabolic alkalosis      1 (0.2)

   Dehydration              7 (0.9)

   Low blood pressure       5 (0.6)

   Giddiness                5 (0.8)

   LFT abnormalities        5 (0.8)

   N/V/D                    4 (0.6)

   Constipation             1 (0.2)

   Anemia                   2 (0.3)

   Thrombocytopenia         4 (0.6)

   Rashes                   4 (0.6)

   Supratherapeutic dose    10 (1.5)

   Subtherapeutic dose      1 (0.2)

  Number of readmissions    

   1                        432 (66.6)

   2                        135 (20.8)

   3                        46 (7.1)

   4                        21 (3.2)

   5                        8 (1.2)

   6                        5 (0.8)

   7                        1 (0.2)

   8                        1 (0.2)
  ---------------------------------------------------

Data shown as mean ± SD or n (%).

Abbreviations: Coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CVD), congestive heart failure (CHF), chronic kidney disease (CKD) benign prostatic hyperplasia (BPH), Parkinson\'s disease (PKD), drug-related problems (DRPs), liver function test (LFT), nausea, vomiting, diarrhea (N/V/D).

###### 

Univariable regression with number of readmissions and variables.

  Variables                                 β (× 10^− 2^)   95% CI (× 10^− 2^)   *p* value
  ----------------------------------------- --------------- -------------------- -----------
  Number of doses per day                   1.23            0.45, 2.02           0.002
  Number of medications                     2.55            1.08, 4.02           \< 0.001
  Age                                       0.029           − 0.69, 0.12         0.16
  Race[a](#tf5000){ref-type="table-fn"}                                          
   If malay                                 − 0.04          − 17.49, 17.41       1.00
   If indian                                17.40           − 1.66, 36.46        0.07
   If others                                24.93           2.26, 47.60          0.03
  Gender[b](#tf6000){ref-type="table-fn"}                                        
   If female                                − 3.00          − 16.18, 10.18       0.66
  Co-morbidities                                                                 
   Diabetes                                 12.84           − 0.28, 25.96        0.06
   Hypertension                             8.44            − 5.33, 22.21        0.23
   Dyslipidemia                             4.25            − 8.93, 17.43        0.53
   CHD                                      5.67            − 19.87, 8.53        0.43
   CVD                                      − 5.33          − 24.99, 14.32       0.59
   Hemiplegia                               17.94           − 41.65, 77.54       0.56
   CHF                                      − 2.86          − 33.15, 27.42       0.85
   COPD                                     9.26            − 16.89, 35.42       0.49
   Asthma                                   15.80           − 5.35, 36.95        0.14
   Liver disease                            29.61           7.34, 51.89          0.009
   CKD                                      − 1.76          − 22.06, 18.55       0.87
   Ulcer disease                            − 24.44         − 54.38, 5.50        0.11
   Osteoarthritis                           7.14            − 35.25, 20.98       0.62
   Osteoporosis                             − 7.59          − 47.81, 32.63       0.71
   Gout                                     3.85            − 22.02, 29.73       0.77
   Cataract                                 9.43            − 17.29, 36.15       0.49
   Anemia                                   16.45           1.29, 31.61          0.03
   Cancer                                   − 14.57         32.83, 48.35         0.22
   BPH                                      4.57            − 22.05, 31.19       0.74
   Thyroid disease                          − 18.57         − 50.61, 13.47       0.26
   Hemorrhoid                               − 0.15          − 119.72, 119.41     1.00
   Epilepsy                                 2.16            − 7.93, 51.26        0.15
   Dementia                                 16.65           − 6.80, 40.11        0.16
   Depression                               13.23           − 9.97, 36.42        0.26
   Alzheimer\'s disease                     − 21.25         − 82.93, 40.44       0.5
   Schizophrenia                            38.75           11.43, 66.07         0.005
   PKD                                      − 6.53          − 46.66, 33.59       0.75
  Non-compliance                            25.20           − 0.58, 50.91        0.06

Abbreviations: Coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CVD), congestive heart failure (CHF), chronic kidney disease (CKD), benign prostatic hyperplasia (BPH) and Parkinson\'s disease (PKD).

Reference group:

Chinese.

Male.

###### 

Generalized linear mixed model of number of readmissions with number of doses per day.

  Variables                                               β (× 10^− 2^)   95% CI (× 10^− 2^)   *p* value
  ------------------------------------------------------- --------------- -------------------- -----------
  Number of doses per day                                 1.14            0.38, 1.90           0.003
  Race[a](#tf0005){ref-type="table-fn"}                                                        
   If Malay                                               0.81            − 16.05, 17.67       0.92
   If Indian                                              13.31           − 5.12, 31.74        0.16
   If others                                              24.69           3.42, 31.74          0.02
  Co-morbidities                                                                               
   Liver disease                                          32.72           11.99, 53.44         0.002
   Schizophrenia                                          44.17           19.17, 69.17         \< 0.001
  Drug-related problem[b](#tf0010){ref-type="table-fn"}                                        
   Non-compliance                                         31.75           7.94, 55.55          0.009

Reference group:

Chinese.

Absence of drug-related problem.

###### 

Generalized linear mixed model of number of readmissions with number of medications.

  Variables                                               β (× 10^− 2^)   95% CI (× 10^− 2^)   *p* value
  ------------------------------------------------------- --------------- -------------------- -----------
  Number of medications                                   2.31            0.88, 3.73           0.002
  Race[a](#tf0015){ref-type="table-fn"}                                                        
   If Malay                                               1.67            − 15.19, 18.52       0.85
   If Indian                                              13.32           − 5.08, 31.75        0.16
   If others                                              24.58           3.33, 45.82          0.02
  Co-morbidities                                                                               
   Liver disease                                          31.66           10.90, 52.42         0.003
   Schizophrenia                                          43.77           18.81, 68.74         \< 0.001
  Drug-related problem[b](#tf0020){ref-type="table-fn"}                                        
   Non-compliance                                         31.75           7.94, 55.56          0.009

Reference group:

Chinese.

Absence of drug-related problem.
